Benzodiazepine use disorder
A pattern of benzodiazepine use marked by impaired control, continued use despite harm, tolerance, and withdrawal, most often beginning with a prescription for anxiety or insomnia continued past its intended short course; management is a sequenced deprescribing taper after converting to a long-acting agent, paired with a non-benzodiazepine treatment of the underlying disorder.
- Topic reviewThe full article, organized the way the exam asks it.
- ABIM-format MCQsVignettes with an explanation for every wrong answer.
- Key factsThe numbers and thresholds worth memorizing, up front.
- AI tutorMedBrain answers the question you're stuck on.
What this article covers
- Overview
Definition: a problematic pattern of benzodiazepine use causing clinically significant impairment, built from the impaired-control, social-impairment, risky-use, and pharmacologic (tolerance…
- Epidemiology
Prescribing-dominant route: benzodiazepine exposure is repeatedly tied to prescribing for anxiety, insomnia, and alcohol or sedative withdrawal, consistent with a population that begins with a…
- Risk factors
Prescription continued past its intended course: initiation for generalized anxiety disorder (GAD), panic disorder, or insomnia with continuation beyond the 2 to 4 week window meant for short-term control.
- Pathophysiology
Receptor mechanism: benzodiazepines increase the frequency (not duration, as with barbiturates) of GABA-A chloride channel opening, hyperpolarizing the neuron and reducing excitability.
- Clinical features
Pattern-of-use threshold: the model for a problematic pattern of substance use, illustrated for alcohol use disorder, rests on impaired control, social impairment, risky use, and the pharmacologic…
- Differential diagnosis
Benzodiazepine withdrawal: anxiety, insomnia, agitation, and seizure, but a time-limited syndrome tied to dose reduction, not the chronic pattern of use; onset is 24 to 48 hours after a short-acting…
- Diagnosis
What confirms it: the diagnosis is clinical, from a history meeting the pattern-of-use threshold above, not a laboratory cutoff; a positive urine benzodiazepine screen alone confirms exposure, not a use disorder.
- Management
First, stabilize acute intoxication or active withdrawal before addressing the use disorder: support airway and ventilation for sedation or respiratory depression; manage active withdrawal per benzodiazepine withdrawal, not a taper.
- Complications
Overdose, especially with a co-ingestant: rarely fatal alone, but respiratory depression becomes life-threatening when combined with an opioid, alcohol, or a barbiturate, all converging on the same pathway.
- Prognosis
Agent half-life predicts course: a patient on a long-acting agent tends to self-taper with a milder course than one on a short-acting, high-potency agent, whose withdrawal begins earlier (24 to 48 hours) and runs more severe.
- Prevention
Limit new prescriptions to the intended short course: treat severe acute anxiety for no more than 2 to 4 weeks, with an explicit stop date discussed at prescribing.
Read the whole article
Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.
Related articles
- Benzodiazepine withdrawal
Benzodiazepine withdrawal is the abstinence syndrome that follows abrupt discontinuation or rapid dose reduction after regular use, and like alcohol withdrawal it can be fatal through seizures and delirium, unlike opioid withdrawal. Management reinstates the drug, converts to a long-acting agent such as diazepam, and tapers the total daily dose by 10 to 25% every 1 to 2 weeks, reserving phenobarbital for refractory or severe cases.
- Alcohol use disorder
Alcohol use disorder is a chronic pattern of drinking meeting 2 or more of 11 DSM-5 criteria within a 1-year period, screened with the CAGE or AUDIT-C and confirmed by history. First-line management combines a brief behavioral intervention and cognitive behavioral therapy with naltrexone or acamprosate, reserving disulfiram for highly motivated patients who can maintain abstinence.
- Opioid use disorder
Opioid use disorder is a maladaptive pattern of opioid use causing significant impairment or distress, diagnosed by meeting 2 or more of 11 substance use disorder criteria within a 12-month period. First-line treatment is medication for opioid use disorder: buprenorphine or methadone maintenance for ongoing agonist therapy, or naltrexone once the patient is confirmed opioid-free, paired with psychosocial care and take-home naloxone.
- Cannabis use disorder
Cannabis use disorder is a maladaptive pattern of cannabis use meeting 2 or more of 11 substance use disorder criteria within 12 months, presenting with CB1-receptor-mediated intoxication, a real but not dangerous withdrawal syndrome, and cannabinoid hyperemesis syndrome in heavy users. There is no approved medication for the disorder itself; first-line treatment is motivational interviewing and cognitive behavioral therapy, with supportive care for withdrawal and cessation of cannabinoids for hyperemesis.
- Generalized anxiety disorder
Generalized anxiety disorder is excessive, hard-to-control worry about multiple life domains occurring more days than not for at least 6 months, with at least 3 of 6 associated physical symptoms and functional impairment. Screen with the GAD-7 after excluding hyperthyroidism and substance use, then treat first-line with cognitive behavioral therapy and/or an SSRI or SNRI such as escitalopram or venlafaxine extended-release, reserving benzodiazepines for short-term severe symptom control only.
- Insomnia
Insomnia is difficulty with sleep initiation, maintenance, or quality despite adequate opportunity for sleep, with daytime dysfunction; it becomes chronic insomnia disorder once symptoms occur at least 3 nights per week for at least 3 months. Treat first-line with cognitive behavioral therapy for insomnia, reserving hypnotics such as zolpidem, eszopiclone, or low-dose doxepin for refractory or short-term use.
- Delirium
Delirium is an acute, fluctuating disturbance of attention and awareness caused by an underlying medical, toxic, or metabolic insult. Diagnosis rests on the Confusion Assessment Method; management is identification and treatment of the precipitating cause plus withdrawal of deliriogenic drugs, reserving antipsychotics for safety only.